Cytokinetics Up 9% (CYTK)
Cytokinetics, Inc. (NASDAQ: CYTK) shares are significantly higher this morning, gaining 9% to $1.69, a gain of 14 cents on 27,000 shares so far this morning.
Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.